Virtual Mission May 2021

The virtual Mission will take place on 10-12 May 2021. The program offers a thematic approach:

10 May: Microbial Diagnostics
11 May: Antimicrobials and antimicrobial treatments
12 May: Preventives (& vaccines) and stewardship tools

Event hashtag: #AMRMissionUK

Tentative online program (BST; UK time)

10 MAY: MICROBIAL DIAGNOSTICS Chairperson: Dr Peter Dirken; Innovate UK
01:00 – 01:15 pm	Welcome by Dr Ruth McKernan CBE; Neuroscientist, businesswoman and innovation leader.
01:15 – 01:45 pm	Impact of microbial diagnostics on the curbing of AMR in a UK perspective. ^{Prof Till Bachmann; University of Edinburgh and Thematic Champion Diagnostics (UK)}
01:45 – 02:15 pm	Diagnostic innovation to combat AMR: pains and pearls from an industry viewpoint. _{^{Dr Mark Miller; Executive VP; Chief Medical Officer, bioMérieux (F)}}
02:15 – 02:30 pm	How to fund innovation and global collaboration ^{Jo Frost; Innovate UK (UK)}
02:30 – 02:45 pm	How NIHR can boost collaboration in the UK ^{Dr Mimoza Hoti; National Institute for Health Research (UK)}
02:45 – 03:00 pm	Q&A
03:00 – 06:00 pm	Partnering Program Due to the unexpectedly high interest in the partnering sessions, it was decided to hold the informal networking during the physical mission later this year.
11 MAY: ANTIMICROBIALS Chairperson: Dr Phil Packer; Innovate UK
01:00 – 01:15 pm	Welcome by Dr Tim Jinks, Head of Drug Resistant Infections Program – Wellcome Trust (UK)
01:15 – 01:45 pm	Small But Crucial – The Role of Biotech in Innovating Antibiotic R&D ^{Dr David Powell; CSO Summit Therapeutics and Thematic Champion Antimicrobials (UK)}
01:45 – 02:15 pm	The future of AMR reimbursement: What types of products will succeed? _{^{Dr John Rex; Chief Medical Officer, F2G Ltd. (USA), Editor-in-Chief, AMR Solutions, Operating Partner, Advent Life Sciences Adjunct Professor of Medicine, McGovern Medical School, Houston, Texas, USA}}
02:15 – 02:30 pm	How to fund innovation and global collaboration ^{Jo Frost; Innovate UK (UK)}
02:30 – 02:45 pm	The Human Microbiome and its defensive actions against AMR ^{Prof Julian Marchesi; Imperial College London (UK)}
02:45 – 03:00 pm	Q&A
03:00 – 06:00 pm	Partnering Program Due to the unexpectedly high interest in the partnering sessions, it was decided to hold the informal networking during the physical mission later this year.
12 MAY: PREVENTION & STEWARDSHIP Chairperson: Dr Maarten B.M. van Dongen; AMR Insights
01:00 – 01:15 pm	Welcome by Santiago Gonzalez; Senior Policy Advisor to Senator Michael Bennet, Colorado (USA)
01:15 – 01:45 pm	Potential impact of vaccination on curbing AMR from a UK and global perspective ^{Prof Cal MacLennan, Bacterial Vaccines, Global Health – Enteric and Diarrheal Diseases, Bill & Melinda Gates Foundation; Senior Clinical Fellow & Jenner Investigator, Jenner Institute, University of Oxford; Professor of Vaccine Immunology & Director of BactiVac Bacterial Vaccines Network, University of Birmingham}
01:45 – 02:15 pm	Innovation and global collaboration iiCON: developing infectious disease therapeutics. ^{Prof Janet Hemingway; Director Liverpool School of Tropical Medicine (LSTM; UK)}
02:15 – 02:30 pm	How to fund innovation and global collaboration ^{Jo Frost; Innovate UK (UK)}
02:30 – 02:45 pm	Development, evaluation, and deployment of diagnostic tests for precision antimicrobial prescribing ^{Dr Philip Turner, NIHR Community Healthcare MedTech and IVD Co-operative, University of Oxford (UK)}
02:45 – 03:00 pm	Q&A
03:00 – 03:15 pm	Closure of the Virtual Mission & look ahead to the Physical Mission in October
03:00 – 06:00 pm	Partnering Program Due to the unexpectedly high interest in the partnering sessions, it was decided to hold the informal networking during the physical mission later this year.